Authors: MCLAUGHLIN P CABANILLAS F GRILLOLOPEZ AJ LINK BK LEVY R CRUCZMAN M HEYMAN MR WILLIAMS M JAIN W BENCEBRUCKLER I HO AD LISTER J ROSENBERG J DALLAIRE BK SHEN D

Citation: P. Mclaughlin et al., IDEC-C2B8 ANTI-CD20 ANTIBODY - FINAL REPORT ON A PHASE-III PIVOTAL TRIAL IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/, Blood, 88(10), 1996, pp. 349-349

Authors: MCLAUGHLIN P CABANILLAS F GRILLOLOPEZ AJ LINK GL LEVY R CRUCZMAN M HEYMAN MR WILLIAMS M JAIN V BENCEBRUCKLER L HO AD LISTER J WEY K SHUEY S PARKER E

Citation: P. Mclaughlin et al., PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE ANTI-CD20 ANTIBODY (MAB) IDEC-C2B8 IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/, Blood, 88(10), 1996, pp. 350-350